Nothing
Code
t_ae_pt_slide(testdata$adsl, testdata$adae, "TRT01A", 2)
Output
Adverse Events table
————————————————————————————————————————————————————————————————————————————————————————
MedDRA Preferred Term N (%) A: Drug X B: Placebo C: Combination All Patients
————————————————————————————————————————————————————————————————————————————————————————
dcd D.2.1.5.3 37 (27.6%) 46 (34.3%) 50 (37.9%) 133 (33.2%)
dcd A.1.1.1.1 45 (33.6%) 31 (23.1%) 52 (39.4%) 128 (32.0%)
dcd B.2.2.3.1 38 (28.4%) 40 (29.9%) 45 (34.1%) 123 (30.8%)
dcd A.1.1.1.2 41 (30.6%) 39 (29.1%) 42 (31.8%) 122 (30.5%)
dcd D.1.1.1.1 42 (31.3%) 32 (23.9%) 46 (34.8%) 120 (30.0%)
dcd B.2.1.2.1 39 (29.1%) 34 (25.4%) 46 (34.8%) 119 (29.8%)
dcd C.2.1.2.1 28 (20.9%) 36 (26.9%) 48 (36.4%) 112 (28.0%)
dcd D.1.1.4.2 38 (28.4%) 34 (25.4%) 40 (30.3%) 112 (28.0%)
dcd B.1.1.1.1 38 (28.4%) 37 (27.6%) 36 (27.3%) 111 (27.8%)
dcd C.1.1.1.3 36 (26.9%) 34 (25.4%) 36 (27.3%) 106 (26.5%)
Code
t_ae_pt_slide(testdata$adsl, testdata$adae, "TRT01A", 28, prune_by_total = TRUE)
Output
Adverse Events table
————————————————————————————————————————————————————————————————————————————————————————
MedDRA Preferred Term N (%) A: Drug X B: Placebo C: Combination All Patients
————————————————————————————————————————————————————————————————————————————————————————
dcd D.2.1.5.3 37 (27.6%) 46 (34.3%) 50 (37.9%) 133 (33.2%)
dcd A.1.1.1.1 45 (33.6%) 31 (23.1%) 52 (39.4%) 128 (32.0%)
dcd B.2.2.3.1 38 (28.4%) 40 (29.9%) 45 (34.1%) 123 (30.8%)
dcd A.1.1.1.2 41 (30.6%) 39 (29.1%) 42 (31.8%) 122 (30.5%)
dcd D.1.1.1.1 42 (31.3%) 32 (23.9%) 46 (34.8%) 120 (30.0%)
dcd B.2.1.2.1 39 (29.1%) 34 (25.4%) 46 (34.8%) 119 (29.8%)
dcd C.2.1.2.1 28 (20.9%) 36 (26.9%) 48 (36.4%) 112 (28.0%)
dcd D.1.1.4.2 38 (28.4%) 34 (25.4%) 40 (30.3%) 112 (28.0%)
Code
t_ae_pt_slide(testdata$adsl, testdata$adae, "TRT01A", 30, prune_by_total = TRUE)
Output
Adverse Events table
————————————————————————————————————————————————————————————————————————————————————————
MedDRA Preferred Term N (%) A: Drug X B: Placebo C: Combination All Patients
————————————————————————————————————————————————————————————————————————————————————————
dcd D.2.1.5.3 37 (27.6%) 46 (34.3%) 50 (37.9%) 133 (33.2%)
dcd A.1.1.1.1 45 (33.6%) 31 (23.1%) 52 (39.4%) 128 (32.0%)
dcd B.2.2.3.1 38 (28.4%) 40 (29.9%) 45 (34.1%) 123 (30.8%)
dcd A.1.1.1.2 41 (30.6%) 39 (29.1%) 42 (31.8%) 122 (30.5%)
dcd D.1.1.1.1 42 (31.3%) 32 (23.9%) 46 (34.8%) 120 (30.0%)
Code
t_ae_pt_soc_slide(testdata$adsl, testdata$adae, "TRT01A", 2)
Output
Adverse Events table
————————————————————————————————————————————————————————————————————————————————————————
MedDRA System Organ Class
MedDRA Preferred Term N (%) A: Drug X B: Placebo C: Combination All Patients
————————————————————————————————————————————————————————————————————————————————————————
cl A.1
dcd A.1.1.1.1 45 (33.6%) 31 (23.1%) 52 (39.4%) 128 (32.0%)
dcd A.1.1.1.2 41 (30.6%) 39 (29.1%) 42 (31.8%) 122 (30.5%)
cl B.1
dcd B.1.1.1.1 38 (28.4%) 37 (27.6%) 36 (27.3%) 111 (27.8%)
cl B.2
dcd B.2.2.3.1 38 (28.4%) 40 (29.9%) 45 (34.1%) 123 (30.8%)
dcd B.2.1.2.1 39 (29.1%) 34 (25.4%) 46 (34.8%) 119 (29.8%)
cl C.1
dcd C.1.1.1.3 36 (26.9%) 34 (25.4%) 36 (27.3%) 106 (26.5%)
cl C.2
dcd C.2.1.2.1 28 (20.9%) 36 (26.9%) 48 (36.4%) 112 (28.0%)
cl D.1
dcd D.1.1.1.1 42 (31.3%) 32 (23.9%) 46 (34.8%) 120 (30.0%)
dcd D.1.1.4.2 38 (28.4%) 34 (25.4%) 40 (30.3%) 112 (28.0%)
cl D.2
dcd D.2.1.5.3 37 (27.6%) 46 (34.3%) 50 (37.9%) 133 (33.2%)
Code
t_ae_pt_soc_slide(testdata$adsl, testdata$adae, "TRT01A", 28, prune_by_total = TRUE)
Output
Adverse Events table
————————————————————————————————————————————————————————————————————————————————————————
MedDRA System Organ Class
MedDRA Preferred Term N (%) A: Drug X B: Placebo C: Combination All Patients
————————————————————————————————————————————————————————————————————————————————————————
cl A.1
dcd A.1.1.1.1 45 (33.6%) 31 (23.1%) 52 (39.4%) 128 (32.0%)
dcd A.1.1.1.2 41 (30.6%) 39 (29.1%) 42 (31.8%) 122 (30.5%)
cl B.2
dcd B.2.2.3.1 38 (28.4%) 40 (29.9%) 45 (34.1%) 123 (30.8%)
dcd B.2.1.2.1 39 (29.1%) 34 (25.4%) 46 (34.8%) 119 (29.8%)
cl C.2
dcd C.2.1.2.1 28 (20.9%) 36 (26.9%) 48 (36.4%) 112 (28.0%)
cl D.1
dcd D.1.1.1.1 42 (31.3%) 32 (23.9%) 46 (34.8%) 120 (30.0%)
dcd D.1.1.4.2 38 (28.4%) 34 (25.4%) 40 (30.3%) 112 (28.0%)
cl D.2
dcd D.2.1.5.3 37 (27.6%) 46 (34.3%) 50 (37.9%) 133 (33.2%)
Code
t_ae_pt_soc_slide(testdata$adsl, testdata$adae, "TRT01A", 30, prune_by_total = TRUE)
Output
Adverse Events table
————————————————————————————————————————————————————————————————————————————————————————
MedDRA System Organ Class
MedDRA Preferred Term N (%) A: Drug X B: Placebo C: Combination All Patients
————————————————————————————————————————————————————————————————————————————————————————
cl A.1
dcd A.1.1.1.1 45 (33.6%) 31 (23.1%) 52 (39.4%) 128 (32.0%)
dcd A.1.1.1.2 41 (30.6%) 39 (29.1%) 42 (31.8%) 122 (30.5%)
cl B.2
dcd B.2.2.3.1 38 (28.4%) 40 (29.9%) 45 (34.1%) 123 (30.8%)
cl D.1
dcd D.1.1.1.1 42 (31.3%) 32 (23.9%) 46 (34.8%) 120 (30.0%)
cl D.2
dcd D.2.1.5.3 37 (27.6%) 46 (34.3%) 50 (37.9%) 133 (33.2%)
Any scripts or data that you put into this service are public.
Add the following code to your website.
For more information on customizing the embed code, read Embedding Snippets.